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Correspondence Upper Limits of Physiological CardiacAdaptation in Ultramarathon RunnersTo the Editor: Physiologic left ventricular (LV) hypertrophy is
common in endurance-trained athletes (1). Controversially, a
recent report from Japan suggested that a new upper limit for
physiological LV hypertrophy might be present in ultramarathon
runners (2). Specifically, in 291 male Japanese runners, 11% had a
left ventricular internal dimension (LVIDd) 70 mm. Further-
more, maximal septal (interventricular septal thickness at end-
diastole [IVSd]: 19 mm), posterior wall (posterior wall thickness at
end-diastole [PWTd]: 15 mm), left atrial (left atrial dimension
[LAD]: 49 mm), and aortic root (aortic root dimension [AoRt]: 50
mm) dimensions were considerably larger than previously sug-
gested (1). These data generated considerable critical comment
and concern (3) and present problems for cardiovascular screening
of such athletes. Interpretation of the data of Nagashima et al. (2)
is further limited by no assessment of LV function, and extrapo-
lation to female athletes is required. Given these issues, it was
important to replicate this work in a broad age range of male and
female ultramarathon runners training and competing in North
America. We hypothesized that LV structure and function in
North American ultramarathon runners would not exhibit the
extreme levels of hypertrophy observed in Japanese athletes.
Over a period of 3 years (2007 to 2009) we recruited 165 (39
women) ultramarathon runners (mean age [range]: 44  9 [24 to
6] years) at the Western States Endurance Run, a 100-mile trail
un in California. All runners were examined 1 to 3 days before
ace start in a field laboratory. The cohort self-reported no personal
r early family history of cardiovascular disease, no current medi-
ation use, and training details as follows: 16  11 (2 to 48)
raining years, 59  21 (15 to 120) running miles/week before the
vent, and 46  53 (3 to 500) completed ultramarathon runs.
Initially we recorded data for: body mass: 70.9  12.1 (41.0 to
100.5) kg; height: 1.75  0.10 (1.47 to 1.97) m; body surface area:
1.86 0.20 (1.35 to 2.19) m2; resting heart rate: 58 9 (38 to 83)
beats/min; and systolic: 117 10 (90 to 148) mmHg and diastolic
blood pressure: 76  8 (48 to 90) mm Hg.
All runners underwent an echocardiographic scan following
American Society of Echocardiography guidelines with a commer-
cially available ultrasound imaging system (Vivid I, GE Health-
care, Ltd., Horton, Norway). Conventional parasternal M-mode
recordings of the LV were obtained for the assessment of LVIDd,
IVSd, PWTd, AoRt, and LAD. The LV mass was calculated, and
all structural data were allometrically scaled (4) to remove the
influence of body surface area (BSA). Apical 2- and 4-chamber
data were acquired for the assessment of LV end-diastolic and
end-systolic volumes, with Simpson’s biplane method, and the
estimation of ejection fraction. Transmitral peak early and atrial
filling velocities were recorded with pulsed-wave Doppler and peak
septal systolic and early diastolic mitral annular tissue velocities
were acquired with color tissue Doppler imaging. From these data
the ratios peak early to atrial LV filling velocities and peak earlyfilling velocity/early diastolic mitral annular tissue velocity were
calculated. The LV structural and functional data were described
for the whole cohort, and differences between male and female
runners were assessed with independent t tests.
Data for absolute and body-sized scaled LV dimensions as well
as LV function are contained in Table 1. Maximal data for IVSd
(14 mm), PWTd (12 mm), LVIDd (62 mm), AoRt (38 mm), and
LAD (47 mm) did not approach data reported in the Japanese
study (2) but were similar to multiple studies from North America
or Europe (1). In all runners, including those with the largest LV
dimensions, resting LV function was normal. The current data
allay fears from clinicians related to the potential for high false
positive rates and significant diagnostic uncertainty when per-
forming cardiovascular screening in ultramarathon runners.
Indeed, the potential for an ultramarathon runner to present for
a cardiovascular screening session in North America with an
LV, AoRt, or LAD within or even beyond the “grey zone” is
reduced significantly.
The explanation for the substantial differences in cardiac di-
mensions between Japanese and North American ultramarathon
runners is probably complex. It is unlikely related to mean or age
range per se, because these data were similar in both groups.
Interestingly, age partially predicted LV morphology in Japanese
runners but not in the current study. It is unlikely that the Japanese
runners were more highly trained, but comparison of training
status was difficult on the basis of available data (1). Again, training
data did partially predict cardiac dimensions in Japanese runners
but did not in our cohort despite heterogeneous training and
performance data. Conversely, although BSA was associated with
cardiac dimensions in North American ultramarathon runners, this
was not the case in Japan, where mean BSA was lower but the
range was similar to the current study. Whether the extreme
cardiac dimensions in some Japanese athletes were representative
of some pathology cannot be determined, because no data for LV
function were presented. Absence of pathology in the North
American runners is supported by normal LV function and a lack
of self-report indication of cardiovascular disease risk; however, we
cannot conclusively rule out early or silent disease in the current
cohort, and this could be assessed in future studies. A genetic
contribution to the larger cardiac dimensions in Japan cannot be
ruled out but is impossible to identify from the current studies.
Mean and maximum absolute cardiac dimensions were signifi-
cantly higher in male ultramarathon runners, which mirror data
from other studies of male and female endurance athletes (5).
When cardiac dimensions were scaled allometrically for individual
differences in BSA, most gender differences were reduced, re-
moved, or—in the case of LV end-diastolic volume—reversed.
Clearly, this suggests that a large component of any sex-based
difference in cardiac morphology is due to differences in body size
and composition. Furthermore, this provides more support for the
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intra- and inter-group comparisons (4). Data for LV function were
not different between sexes.
In summary, the LV, left atrial, and aortic root dimensions of
male and female ultramarathon runners training and competing in
North America did not approach the exaggerated limits previously
reported in Japanese athletes (2). The LV function was normal,
and scaling of cardiac morphology data for BSA removed most
differences between male and female runners. These data have
clear implications for the differentiation of pathological from
physiological LV hypertrophy when screening such athletes.
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LV Structural and Functional Data in Male and FemaleTable 1 LV Structural and Functional Data in Male
Whole Cohort
(n  165)
LVIDd (cm) 5.2 0.4 (4.2–6.2) 5.3
LVIDd/BSA0.5 3.8 0.3 (3.2–4.5) 3.8
IVSd (cm) 1.1 0.2 (0.6–1.4) 1.1
IVSd/BSA0.5 0.8 0.1 (0.5–1.0) 0.8
PWTd (cm) 0.9 0.1 (0.6–1.2) 1.0
PWTd/BSA0.5 0.7 0.1 (0.5–0.9) 0.7
LV mass (g) 180 46 (89–300) 193
LV mass/BSA1.5 70 13 (39–105) 71
LAD (cm) 3.6 0.4 (2.5–4.7) 3.7
LAD/BSA0.5 2.7 0.3 (1.9–3.5) 2.7
AoRt (cm) 2.8 0.4 (1.7–3.8) 2.9
AoRt/BSA0.5 2.0 0.3 (1.3–2.9) 2.0
LVEDV (ml) 131 28 (70–222) 137
LVEDV/BSA1.5 52 10 (26–90) 51
LVESV (ml) 46 19 (18–87) 49
LVESV/BSA1.5 18 7 (8–38) 18
EF (%) 65 10 (49–82) 64
E/A 1.44 0.37 (0.72–2.84) 1.41
S’ (cm/s) 9 2 (6–14) 9
E’ (cm/s) 11 2 (6–18) 11
E/E’ 7.16 1.95 (3.80–16.71) 7.12
Data are mean  SD (range).
AoRt aortic root dimension; BSA body surface area; E’ peak s
velocities; EF  ejection fraction; IVSd  interventricular septal thickn
 left ventricular end-diastolic volume; LVESV  left ventricular end-
PWTd  posterior wall thickness at end-diastole; S’  peak septal waBen T. A. Esch, PhDKaren Williams, MSc
Sarah Charlesworth, PhD
Heather Foulds, MSc
Adele Oxborough, BSc
Martin D. Hoffman, MD
Rob Shave, PhD
doi:10.1016/j.jacc.2010.05.070
lease note: Support was received from the Western States Endurance Run
oundation.
EFERENCES
1. Pelliccia A, Culasso F, Di Paolo FM, Maron BJ. Physiologic left
ventricular cavity dilatation in elite athletes. Ann Intern Med 1999;130:
23–31.
2. Nagashima J, Musha H, Takada H, Murayama M. New upper limit of
physiologic cardiac hypertrophy in Japanese participants in the 100-km
ultramarathon. J Am Coll Cardiol 2003;42:1617–23.
3. Thompson PD. Cardiovascular adaptations to marathon running: the
marathoner’s heart. Sports Med 2007;37:444–7.
4. Dewey FE, Rosenthal D, Murphy DJ Jr., Froelicher VF, Ashley EA.
Does size matter? Clinical applications of scaling cardiac size and
function for body size. Circulation 2008;117:2279–87.
5. Riley-Hagan M, Peshock RM, Stray-Gundersen J, Katz J, Ryschon
TW, Mitchell JH. Left ventricular dimensions and mass using magnetic
marathonersFemale Ultramarathoners
ale Female
p Value126) (n  39)
(4.6–6.2) 4.9 0.3 (4.2–5.5) 0.000
(3.2–4.5) 3.9 0.2 (3.4–4.5) 0.129
(0.8–1.4) 1.0 0.1 (0.6–1.2) 0.000
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